High prolidase levels in patients with Familial Mediterranean Fever (FMF)

1. OZEN S, KONE-PAUT I, GÜL A. Colchicine resistance and intolerance in familial mediterranean fever: Definition, causes, and alternative treatments. Semin Arthritis Rheum. 2007; 47(1):115–20.10.1016/j.semarthrit.2017.03.00628413100Search in Google Scholar

2. PROCOPIO V, MANTI S, BIANCO G, CONTI G, ROMEO A, MAIMONE F, et al. Genotype-phenotype correlation in FMF patients: A “non classic” recessive autosomal or “atypical” dominant autosomal inheritance? Gene. 2018; 641:279–86.Search in Google Scholar

3. YANG L, LI Y, DING Y, CHOI K-S, KAZIM AL, ZHANG Y. Prolidase directly binds and activates epidermal growth factor receptor and stimulates downstream signaling. J Biol Chem. 2013; 288(4):2365–75.10.1074/jbc.M112.429159355490723212918Search in Google Scholar

4. SEZER U, ERCIYAS K, ÜSTÜN K, PEHLIVAN Y, ZIYA ŞENYURT S, AKSOY N, et al. Effect of Chronic Periodontitis on Oxidative Status in Patients With Rheumatoid Arthritis. J Periodontol. 2013; 84(6):785–92.10.1902/jop.2012.12017922799756Search in Google Scholar

5. MENG X, GRÖTSCH B, LUO Y, KNAUP KX, WIESENER MS, CHEN X-X, et al. Hypoxia-inducible factor-1α is a critical transcription factor for IL-10-producing B cells in autoimmune disease. Nat Commun. 2018; 9(1):251.10.1038/s41467-017-02683-x577247629343683Search in Google Scholar

6. PENG J, SHEN S, WANG J, JIANG H, WANG Y. Ηypoxia-inducible factor 1-α promotes colon cell proliferation and migration by upregulating AMPK-related protein kinase 5 under hypoxic conditions. Oncol Lett. 2018; 15(3):3639–3645.10.3892/ol.2018.7748579628329467884Search in Google Scholar

7. WU J, CUI H, ZHU Z, WANG L, LI H, WANG D. Effect of HIF1α on Foxp3 expression in CD4 + CD25 − T lymphocytes. Microbiol Immunol. 2014; 58(7):409–15.10.1111/1348-0421.1216824931519Search in Google Scholar

8. PRAS E, LIVNEH A, BALOW JE JR, et al. Clinical differences between North African and Iraqi Jews with familial Mediterranean fever, Am J Med Genet. 1998; 75: 216–9Search in Google Scholar

9. ARE VN, KUMAR A, KUMAR S, GOYAL VD, GHOSH B, BHATNAGAR D, et al. Crystal structure and biochemical investigations reveal novel mode of substrate selectivity and illuminate substrate inhibition and allostericity in a subfamily of Xaa-Pro dipeptidases. Biochim Biophys Acta – Proteins Proteomics. 2017; 1865(2):153–64.10.1016/j.bbapap.2016.10.01627816563Search in Google Scholar

10. BOZKURT M, YÜKSEL H, EM S, OKTAYOGLU P, YILDIZ M, AKDENIZ D, et al. Serum prolidase enzyme activity and oxidative status in patients with Behçet’s disease. Redox Rep. 2014; 19(2):59–64.10.1179/1351000213Y.0000000072683755524225260Search in Google Scholar

11. UÇAR D, EM S, BOZKURT M, OKTAYOGLU P, YÜKSEL HK, ÇAGLAYAN M, et al. Serum Prolidase Activity in Ankylosing Spondylitis and Rheumatoid Arthritis. Clin Med Insights Arthritis Musculoskelet Disord. 2013; 6: 29–33.10.4137/CMAMD.S12602373838023966806Search in Google Scholar

12. BASPINAR S, KIRNAP M, BASPINAR O, DIZDAR OS, KOCER D. Serum prolidase level in ankylosing spondylitis: low serum levels as a new potential gold standard biomarker for disease activity. Rheumatol Int. 2016; 36(11):1609–16.10.1007/s00296-016-3536-x27443556Search in Google Scholar

13. CELIK A, BIRER MN, KILINC M. Serum prolidase activity in systemic sclerosis. Clin Rheumatol. 2017; 36(8):1827–32.10.1007/s10067-017-3677-728534076Search in Google Scholar

14. GUMUS S, YAMAN H, OZCAN O, DENIZ O, KARAMAN B, CAKIR E, et al. Serum prolidase activity in patients with pulmonary tuberculosis. Scand J Clin Lab Invest. 2011; 71(6):467–72.10.3109/00365513.2011.58702121722016Search in Google Scholar

15. YANG Z-C, LIU Y. Hypoxia-Inducible Factor-1α and Autoimmune Lupus, Arthritis. Inflammation. 2016; 39(3):1268–73.Search in Google Scholar

16. BRUNO A, HABIB A, HUA S, DIAS TH. Hypoxia-Inducible Factor (HIF) as a Target for Novel Therapies in Rheumatoid Arthritis. Front Pharmacol Front Pharmacol. 2016; 7:18.Search in Google Scholar